Arcellx, Inc.是一家处于临床阶段的生物技术企业,专注开发用于治疗血液恶性肿瘤、实体瘤等难治性癌症的CAR-T细胞疗法,其核心管线针对肿瘤领域未被满足的医疗需求,服务全球患者群体。
IMVT
Immunovant, Inc.
营收
$8.4M
净利润
$-75.3M
RLAY
Relay Therapeutics, Inc.
$7.0M
N/A
TSHA
Taysha Gene Therapies, Inc.
$5.5M
$-27.9M
SURG
SurgePays, Inc.
$16.2M
$-13.9M
KYMR
Kymera Therapeutics, Inc.
$11.5M
$-76.6M
GLUE
Monte Rosa Therapeutics, Inc.
$12.8M
$-27.1M
TCI
TRANSCONTINENTAL REALTY INVESTORS INC
$12.1M
$8.3M
CGON
CG Oncology, Inc.
$2.3M
$-41.3M